Objective: The aim of this study was first to assess whether first-trimester serum concentrations of placental growth factor (PlGF) differ between patients with and without gestational diabetes (GDM) and second to test whether there is a correlation between glycosylated hemoglobin (HbA1c), a factor recently shown to be useful in predicting GDM, and PlGF. Methods: PlGF was measured at 8-14 weeks with the Kryptor Immunoassay Analyzer (Brahms, Berlin, Germany). Absolute values were converted to multiples of the median using the software provided by the Fetal Medicine Foundation London. GDM was diagnosed using internationally accepted criteria. HbA1c levels were quantified using the TOSOH G7 automated hemoglobin analyzer. Results: From January to December 2014, 328 women were included in the study, 51 (15.5%) of whom developed GDM. First-trimester PlGF quantification does not discriminate between women at risk to develop GDM and controls, while HbA1c is able to do so. No correlation was found between PlGF and HbA1c. Conclusion: Our findings do not lend support to the hypothesis that early PlGF values are different in women who later develop GDM.

Keywords:
Placental growth factor, First trimester, Maternal serum screening, Gestational diabetes, Glycosylated hemoglobin
1.
Barbour LA: Changing perspectives in pre-existing diabetes and obesity in pregnancy: maternal and infant short- and long-term outcomes. Curr Opin Endocrinol Diabetes Obes 2014;21:257-263.
2.
International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, Dyer AR, Leiva AD, Hod M, Kitzmiler JL, Lowe LP, McIntyre HD, Oats JJ, Omori Y, Schmidt MI: International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010;33:676-682.
3.
HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD, Oats JJ, Persson B, Rogers MS, Sacks DA: Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008;358:1991-2002.
4.
World Health Organization: Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: a report of a WHO/IDF consultation. Geneva, World Health Organization, 2006, pp 1-46.
5.
American Diabetes Association: Standards of medical care in diabetes - 2014. Diabetes Care 2014;37(suppl 1):S14-S80.
6.
Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy: a World Health Organization Guideline. Diabetes Res Clin Pract 2014;103:341-363.
7.
Hughes RC, Moore MP, Gullam JE, Mohamed K, Rowan J: An early pregnancy HbA1c >5.9% is optimal for detecting diabetes and identifies women at increased risk of adverse pregnancy outcomes. Diabetes Care 2014;37:2953-2959.
8.
Fong A, Serra AE, Gabby L, Wing DA, Berkowitz KM: Use of hemoglobin A1c as an early predictor of gestational diabetes mellitus. Am J Obstet Gynecol 2014;211:641.e1-641.e7.
9.
Andraweera PH, Dekker GA, Roberts CT: The vascular endothelial growth factor family in adverse pregnancy outcomes. Hum Reprod Update 2012;18:436-457.
10.
Redman CW, Sargent IL: Placental stress and pre-eclampsia: a revised view. Placenta 2009;30(suppl A):S38-S42.
11.
Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH: Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008;32:732-739.
12.
Poon LC, Zaragoza E, Akolekar R, Anagnostopoulos E, Nicolaides KH: Maternal serum placental growth factor (PlGF) in small for gestational age pregnancy at 11(+0) to 13(+6) weeks of gestation. Prenat Diagn 2008;28:1110-1115.
13.
Ong CY, Lao TT, Spencer K, Nicolaides KH: Maternal serum level of placental growth factor in diabetic pregnancies. J Reprod Med 2004;49:477-480.
14.
Tsiakkas A, Duvdevani N, Wright A, Wright D, Nicolaides KH: Serum placental growth factor in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol 2015;45:591-598.
15.
Eleftheriades M, Papastefanou I, Lambrinoudaki I, Kappou D, Lavranos D, Akalestos A, Souka AP, Pervanidou P, Hassiakos D, Chrousos GP: Elevated placental growth factor concentrations at 11-14 weeks of gestation to predict gestational diabetes mellitus. Metabolism 2014;63:1419-1425.
16.
Weycamp CW, Mosca A, Gillery P, Panteghini M: The analytical goals for hemoglobin A(1c) measurement in IFCC units and national glycohemoglobin standardization program units are different. Clin Chem 2011;57:1204-1206.
17.
Burtis CA, Ashwood ER, Bruns DE: Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, ed 4. St. Louis, Elsevier Saunders, 2006.
18.
Sacks DA, Hadden DR, Maresh M, Deerochanawong C, Dyer AR, Metzger BE, Lowe LP, Coustan DR, Hod M, Oats JJ, Persson B, Trimble ER; HAPO Study Cooperative Research Group: Frequency of gestational diabetes mellitus at collaborating centers based on IADPSG consensus panel-recommended criteria: the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Diabetes Care 2012;35:526-528.
19.
Cheng R, Ma JX: Angiogenesis in diabetes and obesity. Rev Endocr Metab Disord 2015;16:67-75.
20.
Geva E, Ginzinger DG, Zaloudek CJ, Moore DH, Byrne A, Jaffe RB: Human placental vascular development: vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1, and angiopoietin-2. J Clin Endocrinol Metab 2002;87:4213-4224.
21.
Huynh J, Dawson D, Roberts D, Bentley-Lewis R: A systematic review of placental pathology and maternal diabetes mellitus. Placenta 2015;36:101-114.
22.
Cvitic S, Desoye G, Hiden U: Glucose, insulin, and oxygen interplay in placental hypervascularisation in diabetes mellitus. Biomed Res Int 2014;2014:145846.
23.
Lassance L, Miedl H, Absenger M, Diaz-Perez F, Lang U, Desoye G, Hiden U: Hyperinsulinemia stimulates angiogenesis of human fetoplacental endothelial cells: a possible role of insulin in placental hypervascularization in diabetes mellitus. J Clin Endocrinol Metab 2013;98:e1438-e1447.
24.
Loukovaara M, Leinonen P, Teramo K, Andersson S: Concentration of cord serum placenta growth factor in normal and diabetic pregnancies. BJOG 2005;112:75-79.
25.
Gonzalez NL, Gonzalez DE, Castro A, Padron E, Plasencia W: Effect of pregestational diabetes mellitus on first trimester placental characteristics: three-dimensional placental volume and power Doppler indices. Placenta 2014;35:147-151.
26.
Akolekar R, Syngelaki A, Poon LC, Wright D, Nicolaides KH: Competing risk model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 2013;33:8-15.
27.
Cohen AL, Wenger JB, James-Todd T, Lamparello BM, Halprin E, Serdy S, Fan S, Horowitz GL, Kim KH, Rana S, Takoudes TC, Wyckoff JA, Thadhani R, Karumanchi SA, Brown FM: The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes. Hypertens Pregnancy 2014;33:81-92.
28.
International Expert Committee: International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-1334.
29.
Nicolaides KH: A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment. Prenat Diagn 2011;31:3-6.
30.
Syngelaki A, Pastides A, Kotecha R, Wright A, Akolekar R, Nicolaides KH: First-trimester screening for gestational diabetes mellitus based on maternal characteristics and history. Fetal Diagn Ther 2015;38:14-21.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.